Zdrowie i gospodarka · 27/12/1999

FDA Withdraws Guidance on Selegiline Hydrochloride Tablets

The Food and Drug Administration (FDA) is withdrawing a guidance document due to outdated thinking on in vivo bioequivalence and in vitro testing for selegiline hydrochloride tablets, which was issued in December 1995.